Biomarkers to Open the Door to Personalized Medicine and Represents a
Seismic Shift for the Pharma Industry
PHILADELPHIA and LONDON, April 29 /PRNewswire-FirstCall/ -- The Scientific business of Thomson Reuters today announced the launch of a new biomarkers report, "Establishing the Standards in Biomarker Research" which gives a detailed introduction to the world of biomarkers, an overview of the regulatory context surrounding them, and highlights ongoing biomarker research in some of the world's leading Pharma companies.
Thomson Reuters has chosen to highlight advances in biomarker research because of its capacity to change the way Pharma companies do business. Biomarkers which are blood-based tests, gene sequences or mutations, mRNA expression profiles or tissue proteins, provide unparalleled evidence of the state of an organism, or indicate normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention.
"Biomarkers seem destined to prove one of the major drivers of pharmaceutical research and drug development in the 21st century," said Jon Brett-Harris, EVP Pharmaceutical and Chemicals Markets, Thomson Reuters. "For example, the presence of a specific antibody in the blood might indicate a specific infection. Once an association between a biomarker and a disease is clearly established, the one can be used to signal the other, and to a high degree of certainty. As well, changes in the prevalence of a biomarker in the organism can immediately and reliably signpost a patient's response to treatment."
Some pharmaceutical companies are already advancing their research and
harnessing the power of biomarkers, which can:
-- Be used to detect the predisposition for disease in a population,
|SOURCE Thomson Reuters|
Copyright©2008 PR Newswire.
All rights reserved